Advertisement vbandhakavi, Author at Pharmaceutical Business review - Page 6 of 72
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

All articles by vbandhakavi 

AstraZeneca divests global rights to Movantik

Movantik is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC). Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: “This divestment